Clinical Relevance of Preformed HLA Donor-Specific Antibodies in Kidney Transplantation

 

Lefaucheur C, Suberbielle-Boissel C, Hill GS, Nochy D, Andrade J, Antoine C, Gautreau C, Charron D, Glotz D

http://www.ncbi.nlm.nih.gov/pubmed/18162086

 

CDC-XM negative patients with preformed DSA detected by ELISA showed a 9-fold higher incidence of AMR than patients without DSA. Eight-year graft survival is significantly lower in patients with preformed DSA compared to patients without preformed DSA (67.9% vs. 77.3%, p=0.03), and this difference was even more significant if patients with DSA and AMR were analyzed separately from patients with DSA and no AMR (43.6% vs. 78.5%). Patients with DSA and no AMR have similar graft survival compared to patients without preformed DSA.